IP Library Granted Patent US 7,850,997
Granted Patent B2
US 7,850,997 · App. 12/052,940 · Granted Dec 14, 2010

Dietary compositions and methods of enhancing lean body mass and exercise performance

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,850,997
App. No.
12/052,940
Granted
Dec 14, 2010
Kind
B2
Abstract

Various compounds can be administered orally to humans or animals for the purpose of enhancing nitric oxide production. Enhancing nitric oxide production is beneficial for those looking to increase lean body mass or enhance exercise performance. Such administration can also be used for the purpose of enhancing nutrient transport for purposes of athletic performance and controlling bodyweight and body fat levels. L-Arginine and alpha amino n-Butryate work synergistically to enhance nitric oxide production and may further be coupled with either and/or a) an inhibitor of nitric oxide breakdown or b) a nitric oxide potentiators or other precursor and serve to accomplish this goal of enhance nitric oxide. The composition may be administered in a variety of ways including capsules, tablets, powdered beverages, bars, gels or drinks.

Claims (16)

1. A composition comprising L-Arginine alpha amino n-butryate.

2. The composition of claim 1 wherein L-Arginine and alpha amino n-butryate are blended together.

3. The composition of claim 1 wherein L-Arginine and alpha amino n-butryate are chemically bonded.

4. The composition of claim 1 further comprising a nitric oxide potentiator or precursor.

5. The composition of claim 4 wherein the nitric oxide potentiator or precursor is selected from a group consisting of: gypenosides (Gynostemma pentaphyllum), Rutaecarpine, 4-Butrybetaine, perillaldehyde Ginseng, or another derivate of L-Arginine (L-Arginine base, L-Arginine Hydrochloride, L-Arginine Pyroglutamate, Arginine Esters, L-Arginine Isocaproate, L-Arginine Alph-Ketoglutarate, and mixtures thereof or L-Citrulline (Base, L-Citrulline Malate, Citrulline Esters, L-Citrulline AICG, and mixtures thereof).

6. A composition according to claim 1 further comprising a nitric oxide breakdown inhibitor.

7. The composition of claim 6 wherein the a nitric oxide breakdown inhibitor is selected from a group consisting of: L-Norvaline, pomegranate or an extract or a derivative thereof, blueberry or an extract or a derivative thereof, grape seed or an extract or a derivative thereof, or red wine or an extract or a derivative thereof.

8. A composition of claim 1 , wherein the composition is prepared in a form selected from a group consisting of: a powder, a liquid, a tablet, a capsule, a pill, a candy, a confection food additive or a gel cap.

9. A method of increasing the lean body mass in a mammal comprising the step of orally administering to a mammal, a therapeutically effective amount of L-Arginine and alpha amino n-butyrate.

10. A method of claim 9 , further comprising the step of: orally administering to a mammal, a composition comprising a therapeutically effective amount of L-Arginine and alpha amino n-butyrate, a nitric oxide precursor, and a nitric oxide potentiator and a nitric oxide breakdown inhibitor.

11. A composition consisting essentially of L-Arginine alpha amino n-butryate, a nitric oxide potentiator or precursor, and a nitric oxide breakdown inhibitor.

12. The composition of claim 11 wherein the nitric oxide potentiator or precursor is selected from a group consisting of gypenosides (Gynostemma pentaphyllum), Rutaecarpine, 4-Butrybetaine, perillaldehyde Ginseng, or another derivate of L-Arginine (L-Arginine base, L-Arginine Hydrochloride, L-Arginine Pyroglutamate, Arginine Esters, L-Arginine Isocaproate, L-Arginine Alph-Ketoglutarate, and mixtures thereof) or L-Citrulline (Base, L-Citrulline Malate, Citrulline Esters, L-Citrulline AICG, and mixtures thereof).

13. The composition of claim 11 wherein the a nitric oxide breakdown inhibitor is selected from a group consisting of: L-Norvaline, pomegranate or an extract or a derivative thereof, blueberry or an extract or a derivative thereof, grape seed or an extract or a derivative thereof, or red wine or an extract or a derivative thereof.

14. A composition according to claim 11 , wherein the composition is prepared in a form selected from a group consisting of: a powder, a liquid, a tablet, a capsule, a pill, a candy, a confection food additive or a gel cap.

15. The composition of claim 11 wherein L-Arginine and alpha amino n-butryate are blended together.

16. The composition of claim 11 wherein L-Arginine and alpha amino n-butryate are chemically bonded.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2014
From: F.H.G. CORPORATION, D.B.A. INTEGRITY NUTRACEUTICALS
To: IN INGREDIENTS, INC.
Reel/Frame 031977/0576 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2011
From: ROMERO, TIM, MR.; MILLER, PETER, MR.
To: FHG CORPORATION D/B/A INTEGRITY NUTRACEUTICALS
Reel/Frame 025600/0176 →
Continuity (2)
Provisional Application 6089604900 · Mar 21, 2007
Related Publication 20080233186A1 · Sep 25, 2008